Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible?
Quirico MelaValeria RuggieroLorenza MontaldoUmberto PisanoLaura MattaCristina Maria PasettoSimona OnaliEnrico CacaceMauro Giovanni CartaLucia BarcaLuchino ChessaPublished in: HIV clinical trials (2018)
The proposed protocol of cholecalciferol and dietary calcium supplementation is safe and valid for correcting vitamin D abnormalities in almost all patients as well as reducing PTH levels in a high percentage of patients; however, it is not sufficient for normalization, particularly in patients exposed to tenofovir or efavirenz. At the spine, no significant BMD change was found in any of the therapy groups. At the hip, our data confirm a modest negative effect on bone mass caused by tenofovir and efavirenz.
Keyphrases
- antiretroviral therapy
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- hiv infected
- prognostic factors
- peritoneal dialysis
- stem cells
- hiv positive
- mesenchymal stem cells
- hepatitis c virus
- machine learning
- postmenopausal women
- big data
- stem cell transplantation
- artificial intelligence
- patient reported
- hiv testing
- soft tissue